Text Size

A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01589432
First received: April 30, 2012
Last updated: January 2, 2013
Last verified: January 2013
History of Changes

April 30, 2012
January 2, 2013
April 2012
November 2012   (final data collection date for primary outcome measure)
Spontaneous activity in peripheral c-nociceptors [ Time Frame: 10 minute intervals over 180 minutes ] [ Designated as safety issue: No ]
Spontaneous activity in peripheral c-nociceptor measured through microneurography
Same as current
Complete list of historical versions of study NCT01589432 on ClinicalTrials.gov Archive Site
Pain intensity measurements [ Time Frame: hourly for 4 hours ] [ Designated as safety issue: No ]
Pain intensity reported on a numerical rating scale
Same as current
Not Provided
Not Provided
 
A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy
A Randomized, Double-blind, Placebo and Active-controlled Study of the Electrophysiological Effects of ABT-639 on Spontaneous Activity in C-Nociceptors in Patients With Painful Diabetic Peripheral Neuropathy

People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Diabetic Neuropathic Pain
  • Drug: ABT-639
    two 50 mg oral capsules
  • Drug: Placebo
    2 placebo capsules
  • Drug: Lidocaine
    3mg/kg infusion over 30 minutes
  • Experimental: ABT-639
    Intervention: Drug: ABT-639
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Active Comparator: Lidocaine
    Intervention: Drug: Lidocaine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
39
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Subject is between the ages of 18 to 75 years with a diagnosis of diabetes mellitus and must have a diagnosis of painful distal symmetric diabetic polyneuropathy and presence of ongoing pain due to diabetic peripheral neuropathy for at least 6 months.
  • Subject must have an average score of greater than or equal to 4 on the 24 hour average pain score (0-10 numerical rating scale) collected over approximately 7 days prior to the Baseline Visit.

Exclusion Criteria

  • Subject has clinically symptomatic neuropathic pain conditions that can not be distinguished from diabetic neuropathic pain or interfere with the pain assessments of diabetic neuropathic pain.
  • A subject has newly diagnosed or clinically significant medical conditions or mental disorders that would preclude participation or would interfere with diabetic neuropathic pain assessments or other functions.
  • Subject has clinically significant abnormalities in clinical laboratory tests.
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01589432
M13-383, 2011-005127-40
No
AbbVie ( AbbVie (prior sponsor, Abbott) )
AbbVie (prior sponsor, Abbott)
Not Provided
Study Director: Rita Jain, MD AbbVie
AbbVie
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP